Trial Profile
A phase 2 pilot study to assess daclizumab to improves immune responses induced by rindopepimut, given in combination with temozolomide
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jul 2018
Price :
$35
*
At a glance
- Drugs Rindopepimut (Primary) ; Daclizumab; Temozolomide
- Indications Glioblastoma
- Focus Pharmacodynamics; Therapeutic Use
- 09 Jun 2009 New trial record.
- 31 May 2009 Preliminary data were presented in a poster session at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), according to a Pfizer media release.